Clinical Trial Update: Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical trial update evaluating safety and efficacy of In-111 Pentetreotide for neuroendocrine tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• In-111 Pentetreotide (pentetreotide labeled with indium-111)

Snippet

Sponsor: Radio Isotope Therapy of America | Conditions: Neuroendocrine Tumors | Phase 2, Phase 3 | Status: COMPLETED